Garnet BioTherapeutics has identified the first in a series of cell products which it calls GBT 009, capable of reducing inflammation and promoting healing. In addition, the company has developed proprietary scalable cell manufacturing technology that has largely solved the challenge of commercial manufacturing scale up of patient doses from a single donor source.
“We’re initially developing our cell-based therapy for cosmetic and dermatologic applications where accelerated healing and reduced scarring are desirable, as plastic surgeons often cite scarring as a top patient concern in cosmetic surgical procedures,” Henwood explained. Cosmetic applications such as breast augmentation, abdominoplasty and facelifts represent a market opportunity of more than $1 billion worldwide.
Garnet BioTherapeutics believes that the cell-based therapy may also be applicable for treatment of burns, auto-immune disorders such as psoriasis, and in other conditions where inflammation or scar formation plays an important role in disease pathology.
About Garnet BioTherapeutics
Garnet BioTherapeutics is a clinical stage regenerative medicine company based in Malvern, PA. Garnet cell-product GBT 009, when used topically on the skin or administered internally, releases anti-inflammatory and pro-healing factors that accelerate healing and reduce scarring. The company is currently targeting dermatology applications, with plans to expand into other reconstructive and cosmetic procedures as well as looking at ways to advance the technology for use in orthopedic and cardiovascular surgical procedures, burn treatment, chronic wound healing and auto-immune disorders. For more information, please visit www.garnetbio.com.
